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Purpose: The purpose of the present study was to investigate interaction between ketotifen fumarate 
and anhydrous theophylline in aqueous media of various pH. 
Methods: By using Job’s continuous-variation analysis and Ardon’s spectrophotomeric methods, the 
values of stability constants of  theophylline  with ketotifen were determined at a fixed temperature (37 
0C) at each of the medium pH. In vitro study of protein (bovine albumin, fraction v) binding was carried 
out by equilibrium dialysis method at pH 7.4 to ascertain the influence of ketotifen on the protein binding 
of theophylline. 
Results: Stability constant, ranging between 5.07 and 6.35, were derived from Ardon’s plot, indicating 
that complexes formed, as a result of interaction between the drugs, were comparatively stable. 
However, following theophylline interaction with ketotifen, stability constant was < 1 at gastric pH (0.4 
and 2.0) and 4.12 at intestinal pH. (6.0)The highest degree of protein binding by ketotifen was 98 % and 
the lowest 90 %. For theophylline, the highest and lowest degrees of protein binding were 90 and 85 %, 
respectively. 
Conclusion: Concurrent administration of ketotifen and theophylline would result in the formation of a 
stable complex and this is likely to reduce the therapeutic activities of both drugs. With regard to protein 
binding, the concentration of theophylline increased with decrease in ketotifen concentration.  
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Ketotifen is a benzocycloheptathiophene 
derivative that has been shown to possess 
anti-histaminic and anti-anaphylactic 
properties [1]. It has been demonstrated that 
it can block in vitro release of mediators from 
rat peritoneal mast cells [1]. The drug inhibits 
the release of histamine and leukotriene from 
basophil and lung tissue, antagonizes 
histamine at H1 receptors, inhibits calcium 
uptake, blocks passive cutaneous 
anaphylactic reaction, reverses isoprenaline-
induced beta-adrenoceptor tachyphylaxis, 
and inhibits both allergen-induced and drug-
induced asthma [2].  
 
A number of clinical trials of ketotifen have 
shown it to have a beneficial effect in the 
treatment of asthma [3,4] equivalent to that of 
disodium cromoglycate, which has an 
established place in the treatment of asthma 
[5,6]. Ketotifen, which is useful in the 
treatment of hay fever and asthma, have 
been found to inhibit anaphylactic histamine 
release from animal tissues .  
 
Theophylline, also known as 
dimethylxanthine, is a xanthine with 
bronchodilator properties and is used in the 
treatment of asthma and chronic obstruvtive 
pulmonary disease (COPD). Moreover, 
theophylline has been shown to have some 
anti-inflammatory activities, inhibiting the 
activity of CD4 lymphocytes in-vitro and 
mediator release from mast cells [7]. It also 
inhibits bronchoconstriction produced by 
exercise and challenge testing, and has also 
been shown to have beneficial effects on the 
contraction of the diaphragm, an effect which 
may be particularly useful in patients with 
COPD [8,9].  
 
Drug-drug interaction occurs when one 
therapeutic agent either alters the 
concentration (pharmacokinetic interactions) 
or the biological effect (pharmacodynamic 
interactions) of another agent [10] .The 
clinical significance of a specific drug-drug 
interaction depends on the degree of 
accumulation of the substrate and the 
therapeutic window of the substrate [11]. The 
combination of theophylline and ketotifen is 
often used for respiratory tract infection and 
some suggest the combination is effective 
[12] though others suggest the combination 
may be embryotoxic, with growth retardation, 
morphological abnormalities, etc [13]. The 
present study was designed to evaluate the 
interaction between ketotifen fumarate and 
anhydrous theophylline, as well as the safety 





Drugs and chemicals 
 
Ketotifen fumarate (potency, 95%) and 
anhydrous theophylline (potency, 91%) were 
obtained from Square Pharmaceuticals Ltd, 
Dhaka, Bangladesh, as gifts, and used 
without further purification. Bovine serum 
albumin (fraction V) and semipermeable 
membrane (Medicell, England) were 
purchased from BDH (England). Sodium 
dihydrogen orthophosphate and di-sodium 
hydrogen orthophosphate, used for the 
preparation of buffer solutions were 
purchased from Merck, Germany. Potassium 
chloride, sodium hydroxide, potassium 
hydroxide and other reagents used were all 




For the tests, we used UV-Visible 
spectrometer (model no. UV-1600, 
Shimadzu, Japan), pH meter (Mettler Toledo, 
Switzerland), analytical balance (model AL 
204-S/01, Mettler Toledo, Switzerland), and a 
thermostatted water bath (Shimadzu, Japan). 
A Dunbuff metabolic shakimg incubator 
(Nickel, Electrical Company, England) was 
used to shake the plasma/drug mixtures to 
attain equilibrium. 
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Preparation of standard solutions 
 
Stock solutions of ketotifen fumarate (1X10-3 
M) and anhydrous theophylline (1X10-3 M)  
prepared by dissolving them in distilled water. 
These stock solutions were diluted to desired 
strengths (1X10-5M)  by buffer solutions to 
obtain the working standard solutions. 
 
Absorption spectrum analysis 
 
The absorption characteristics of ketotifen 
fumarate and theophylline, separately, and 
their 1:1, 1:2 and 2:1 mixtures in HCl/NaCl 
buffer solutions (pH 0.4 and 2.0) and 
phosphate buffer (pH 6.0), respectively, were 
obtained and compared with those of each of 
the interacting species [14,15]. The 
concentrations of the sample were kept at 
very dilute levels in each case and the 
measurements made using UV-VIS 
spectrophotometer with a constant 
temperature cell compartment and automatic 
recording unit. The stock solutions of the 
samples were diluted to appropriate levels 
with the respective buffers (1 x 10-5M)  at the 
desired pH and the spectra recorded 
between 400 - 190 nm. The spectra were 
compared with those of the pure samples in 
each case. 
 
Job’s spectrophotometric method  
 
Based on Job’s method [16], a series of 
solutions were prepared in which the 
analytical concentration of one reactant 
(usually the cation) was held constant while 
that of the other was varied. Absorbance of 
series of mixtures of ketotifen fumarate and 
theophylline in varying molar ratios (1:9, 2:8, 
3:7, 4:6, 5:5, 6:4, 7:3, 8:2, 9:1) were 
measured, keeping the total mole constant. 
The absorbance of each of the mixtures was 
subtracted from sum of the values for the free 
drugs. The absorbance difference (D) was 
then plotted against the mole fraction of the 
drug in the mixtures. If the  two straight lines 
of different slopes that intersect at a mole 
ratio that corresponds to the combined ratio 
in the complex are obtained. 
Ardon’s spectrophotometric method [17] 
 
In this method [18], the concentration of 
anhydrous theophylline was fixed (2 x 10-4M) 
while ketotifen concentration was varied. The 
absorbance of the free drug solutions and 
that of the mixtures were measured 
spectrophotometrically at 300 nm at different 
pH. Based on Ardon’s equation (Eq 1), the 
1/(D-CǫA) was plotted against 1/drug, and the 
values of stability constant were calculated 




-1  = {KC (єcom -єA)[B]}
-1  +  { C (єcom - 
єA)}
-1 …………………… (1) 
 
where D = absorbance of the mixture; B = 
molar concentration of the ketotifen fumarate; 
C = molar concentration of the anhydrous 
theophylline; єcom = molar extinction co-
efficient of the complex; and єA = molar 
extinction coefficient of the ketotifen fumarate 
  
Equilibrium dialysis method 
 
The semi-permeable membrane (Medicell, 
England) was activated by digesting with 1M 
NaHCO3 at 70
0C for 4 h, washed with de-
ionised water and immersed in 0.067M 
phosphate buffer at pH 7.4. At first the 
membrane was cut into small pieces, 4 cm in 
length, and taken in a 500 ml beaker 
containing de-ionized water maintained at 65 
- 70 0C. The activated membrane and drug 
solution (ranging from 1 x 10-5M, to 7 x 10-
5M). The mixtures were in a ratio of 1:1 in 60 
ml of phosphate buffer and then shaken 
gently for 6 h in a metabolic shaking 
incubator at 37 0C. Following completion of 
dialysis, the absorbance of the medium was 
measured at 300 nm and the concentration of 
bound and unbound drugs were calculated. 
 
Protein binding (F) was computed from Eq 2 
[18] 
 
F = {[B]-[A] /[B]} x 100 ………………… (2) 
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where, [A] is the molar concentration of the 
free drug in the buffer compartment [B] is the 





The results are expressed as mean ± 
standard error of mean (SEM) values. 
Differences between the means of 
experimental data were analyzed by unpaired 
t-test. A probability value less than 0.05 (p < 




Each of the drugs studied showed absorption 
in the UV-VIS region. The molecular species 
of ketotifen fumarate and theophylline, when 
mixed together, showed some changes in 
their absorption characteristics including shift 
in absorption maxima. The curves obtained 
by Job’s method showed breaks at different 
molar concentrations for the drugs. The curve 
for pH 0.4 medium was exhibited downward 
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Figure 1:  Absorbance difference (D value) at pH 
6.0 (■), pH 2.0 (●) and pH 0.4 (▲) 
 
Continuous variation plot gives information on 
the relative affinities of the complexes and it 
also depends on the intrinsic spectral 
characteristics of each complex [19].  
 
Ardon’s plots is used to evaluate the stability 
constants. When values of 1/(D-CǫA) were 
plotted against 1/Drug (see Figure 2), straight 
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Figure 2: 1/(D-CɛA) values at pH 6.0(▲), pH 0.4 
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Figure 3:  1/(D-CɛA) values at pH 0.4 (●), pH 6.0 
(▲) and pH 2.0 (■). 
 
The values of the stability constants were 
5.12, 6.35 and 5.07 at pH 0.4, 2.0 and 6.0, 
respectively, when ketotifen interacted with 
theophylline, . 
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Figure 4:  Protein binding (%) of ketotifen (▲) and 
ketotifen-theophylline mixture (■) 
 
Figure 4 illustrates the protein binding 
characteristics of ketotifen fumarate, and that 
of theophylline/ketotifen mixture at pH 7.4 
and 37 0C. The highest degree of protein 
binding of ketotifen with bovine serum 
albumin was 98 % and the lowest 90 %. In 
the presence of theophylline, the highest and 





Initial evidence for complexation of ketotifen 
fumarate with theophylline came from 
differences between the spectra of the drugs 
and those of their mixtures in buffer solutions. 
Each compound has its unique molecular 
structure or electronic configuration which is 
responsible for absorption of light. The 
spectra of ketotifen fumarate at different pH 
showed a sharp absorption maximum at 300 
nm but when theophylline was mixed with it in 
2:1 ratio at pH 0.4, the intensity of ketotifen 
peak changed remarkably as absorption 
decreased but the absorption of the 
compound did not shift at pH 0.4. At pH 6, the 
intensity of the peak of ketotifen was altered 
as absorption increased.  
 
Very low stability constant values mean that 
the complex formed due to the interaction of 
the drugs readily dissociates, yielding 
essentially the drugs in ionic form, ranging 
from pH as low as stomach acid (pH 0.4 to 3) 
to as high as physiologic pH 6.0 (pH of main 
extracellular body fluids such as serum and 
lymph). The values of the stability constant, 
which varied between 5.07 and 6.35, indicate 
not only that complexation occured between 
ketotifen and theophylline but also that the 
interaction was pronounced. It can be 
assumed that these two drugs should not be 
co-administered. 
 
In applying Ardon,s method, theophylline was 
taken as the parent drug, and in its 
interaction with ketotifen, lower stability 
constant values were found, indicating readily 
solubility of both drugs and minimum drug-
drug interaction. The degree of protein 
binding of ketotifen decreased with increase 
in the concentration of theophylline attaining 
a steady (plateau) state when the free drug 
concentration was around 5 x 10-5M. On the 
other hand, the theophylline curve also 
declined significantly (p = 0.01) due to protein 
binding of ketotifen fumerate. . 
 
CONCLUSION   
 
Interaction of ketotifen with theophylline 
decreased the free drug concentration of both 
drugs which can result in decreased 
availability of the drugs at receptors. 
Ultimately, one or both drugs may show 
diminished pharmacologic activity. 
Furthermore, ketotifen fumarate and 
theophylline lowered protein binding of 
theophylline, could increase the volume of 
distribution of theophylline. Therefore, caution 
should be exercised during the administration 
of both drugs, pending in vivo experiments to 
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